C-MORE capturing multiorgan effects of COVID-19
Although COVID-19 mostly affects the lungs, some people can develop damage to other organs. The symptoms of COVID-19 can continue for months after the infection. The purpose of this study is to understand the effects of COVID-19 on the health of the:
It will assess how it has affected people's quality of life, mental health and exercise capacity 12 months after the infection, and compare them with people who have not had COVID-19.
Find out more about the C-MORE study on the NIHR website.
Impact of biologic therapy on COVID-19 infection and immunity (CLARITY)
Inflammatory bowel disease (IBD) affects about 1% of the UK population and is usually treated with immunosuppressive drugs. The impact of immunosuppressive drugs on COVID-19 infection and disease severity is unknown but is a concern for patients and clinicians.
This study will provide evidence for safer prescribing of immunomodulator and biologic drugs during COVID-19 and inform public health policy regarding physical distancing measures, and future vaccination strategies.
Find out more about the biologic therapy study on the NIHR website.
Demographic, multi-morbidity and genetic impact on myocardial involvement and its recovery from COVID-19: the COVID-HEART study
Up to 1 in 5 patients hospitalised by COVID-19 have evidence of heart muscle injury as measured from a blood test.
This study will look at how often, and in what way, the heart becomes damaged, and how the heart recovered 6 months later. We need to know how heart muscle damage and recovery is affected by:
- ethnic group
- other medical conditions (such as diabetes, high blood pressure, heart disease and narrowing of blood vessels)
We also want to see if we can improve the diagnosis of viral heart damage from a simple electrocardiogram (ECG) (a test that is used to check the heart's rhythm and electrical activity).Find out more about the COVID-HEART study on the NIHR website.
COVID-19 identification of epitopes and antibodies (COVID-IDEA)
Visit the NIHR BioResource website for information about the COVID-IDEA study.
Our genes determine how likely we are to get life-threatening infections, and when a patient is already sick, different genetic factors determine how likely they are to survive. The GenOMICC (genetics of susceptibility and mortality in critical care) study will identify the specific genes that cause some people to be more likely to get particular infections and more likely to end up being severely ill.
Identifying these genes may help us to use existing treatments better, and to design new treatments to help people survive serious illness. To do this, we will compare cells and DNA (the genetic code that determines all of a person's characteristics found in the cell nucleus) from carefully selected patients with those from healthy people. The study, which started in 2016, will include COVID-19 patients.
There is an urgent need to conduct coordinated clinical research in the early phase of this dynamic development to know more about coronavirus (COVID-19) and to provide an evidence base to inform treatment decisions and an effective public health response. The Clinical Characterisation Protocol for Severe Emerging Infection (ISARIC-4C) study is designed for the rapid, coordinated clinical investigation of patients with confirmed novel coronavirus infection. The study has been designed to maximize the likelihood that as much data as possible is collected and shared rapidly in a format that can be easily aggregated, tabulated and analysed across many different settings globally. The study is designed to have some level of flexibility in order to ensure the widest acceptance.
Post-hospitalisation COVID-19 study: a national consortium to understand and improve long-term health outcomes (PHOSP-COVID)
The COVID-19 pandemic has had a major impact on the UK's health, social care and economy. This study will investigate the chronic health and health economic effects of COVID-19 infection in post-hospitalisation survivors.
The study will have 10,000 participants and will continue to link to participants clinical data for at least 25 years or until the patient has deceased or withdrawn consent.
Find out more about the PHOSP-COVID study on the NIHR website.
Procalcitonin and NEWS2 evaluation for timely identification of sepsis and optimal use of antibiotics in the Emergency Department (PRONTO)
Sepsis is a common, potentially life-threatening complication of infection. The optimal treatment for sepsis includes early recognition, prompt antibiotics and fluids into a vein (IV).
This study aims to improve assessment of patients with suspected sepsis in the emergency department using a 20 minute test. We want to reduce the amount of unnecessary broad spectrum antibiotics used.
Visit the NIHR website for more information about the PRONTO study.